Search Results

Cresilon, Inc. has entered into a Cooperative Research and Development Agreement (“CRADA”) with Walter Reed Army Institute of Research (“WRAIR”), the largest biomedical research facility administered by the U.S. Department of Defense (“DoD”), to advance the development of medical technologies used for treating traumatic brain injuries, particularly those sustained by soldiers on the battlefield.

Adaptive Phage Therapeutics today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database.

Smith+Nephew, the global medical technology company, announced they have entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research.

Virpax Pharmaceuticals Announces Preliminary Results of Probudur TM Pilot Study with the U.S. Army Institute of Surgical Research.

Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has finalized a new Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR).

LabVantage Solutions, Inc., today announced the United States Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a contract to supply its LabVantage Pharma laboratory information management system (LIMS) to the Walter Reed Army Institute of Research (WRAIR)

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company’s Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company’s Board.

Virpax ® Pharmaceuticals, Inc. today announced that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site, has been extended to September of 2024.